We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PTAB to Hold Inter Partes Review of Amgen’s Neupogen Patents
PTAB to Hold Inter Partes Review of Amgen’s Neupogen Patents
The U.S. Patent Trial and Appeals Board (PTAB) has agreed to conduct an inter partes review of two of Amgen’s patents on the chemotherapy drug Neupogen (filgrastim).